EDIT vs NTLA
EDIT and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEDITAS MEDICINE, INC. | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $417.74M | $1.61B |
| P/S | 10.3x | 23.8x |
| Revenue growth (YoY) | 25.4% | 16.9% |
| Earnings growth (YoY) | 32.5% | 20.5% |
| EBIT margin | -394.9% | -651.7% |
| ROE | -152.0% | -56.7% |
| 1y total return | -3.9% | -6.2% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: EDIT vs NTLA
| 지표 | EDIT | NTLA |
|---|---|---|
| 최종 가치 | $901 | $4.9K |
| 총수익률 | -91.0% | -50.9% |
| CAGR | -20.8% | -6.6% |
| 변동성 | 83.5% | 78.2% |
| 샤프 | 0.07 | 0.25 |
| 소르티노 | 0.11 | 0.37 |
| 최대 낙폭 | -98.9% | -96.5% |
공통 거래일 2600일 기준, 2016-05-13 → 2026-09-16 · 무위험수익률 4.11% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)